Ellipses Pharma eyes LSE listing through reverse takeover deal

London-based oncology drug developer, Ellipses Pharma, is exploring a potential LSE Main Market listing through a proposed reverse takeover of Wolfram Resources, with completion targeted for early 2027.

The transaction could provide fresh capital to support the biotechnology group's expanding oncology pipeline.

The company has signed a non-binding Memorandum of Understanding (MoU) with Wolfram, outlining plans for the acquisition of Ellipses' entire issued share capital and the subsequent relisting of the enlarged business on the LSE Main Market under the equity shares (commercial companies) category.

Founded in 2017, Ellipses Pharma specialises in identifying, acquiring and advancing promising cancer drug candidates through clinical development. Its portfolio includes several clinical-stage programmes, supported by clinical trial sites across the United States, Europe and Asia-Pacific.

A successful transaction would give Ellipses access to public equity markets, potentially broadening its funding options as it seeks to advance its clinical programmes and generate further value for shareholders.

Under the proposed structure, consideration is expected to be satisfied through the issue of new ordinary shares in Wolfram. Final transaction terms remain subject to due diligence and negotiations. An additional equity fundraising is also anticipated alongside the proposed acquisition and relisting.

Professor Sir Chris Evans, founder and chair of Ellipses Pharma, said the progress achieved across the company's pipeline made this an appropriate time to pursue a public listing. He added that the transaction could accelerate development activities while providing access to additional investment capital.

Wolfram executive director, Graeme Muir, said the company was encouraged by Ellipses' management expertise and believed the proposed transaction could deliver value for its shareholders.

The LSE recorded just three Main Market listings in the first nine months of 2026, raising £544.8m.



Share Story:

Recent Stories